MedTrace Logo

Pre-approval Access for Janssen's COVID Vaccine VAC31518 for Treating Physician Use

NCT04817657 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2021-03-26

No results posted yet for this study

Summary

The purpose of this Pre-approval access (PAA) program is to provide VAC31518 (Ad26.CoV2.S) vaccine for the prevention of coronavirus disease-2019 (COVID-19) infection. This PAA program may be considered to protect participants against a serious/life-threatening diseases or conditions, where there are no alternative treatments available.

Conditions

  • Healthy

Interventions

BIOLOGICAL

Ad26.COV2.S

Participants will be administered 0.5 milliliter suspension of Ad26.COV2.S 1\*10\^11 virus particles per milliliter (vp/ml) as intramuscular injection.

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    lead INDUSTRY

Principal Investigators

  • Janssen Research & Development, LLC Clinical Trial · Janssen Research & Development, LLC

Eligibility

Sex
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04817657 on ClinicalTrials.gov